Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study
published in: Clinical Lymphoma, Myeloma & Leukemia
date of publication: 2015-03-05
language: English
main subject: diffuse large B-cell lymphoma, rituximab
Cites articles 1
Date
Title
Article - wd:Q41114153